Which companies sell generic Epclusa, and what’s the “manufacturer list price” for 2026?
No reliable, current manufacturer list-price guidance for “generic Epclusa in 2026” is available in the provided information. Generic pricing can also vary by:
- National payer contracts and rebates (so “list price” often differs from what patients actually pay).
- Wholesale acquisition cost vs. manufacturer list price conventions used by different sources.
- Launch timing (a generic may become available in some markets before others).
When will Epclusa generics be able to launch (so 2026 pricing would apply)?
To determine a 2026 generic list price, you first need to know which generic products are actually on the market by then. That depends on patent and exclusivity timing tied to Epclusa’s active ingredients (sofosbuvir/velpatasvir). DrugPatentWatch.com tracks these patent/exclusivity dynamics and is often the fastest way to identify who can launch and when. [1]
What to check if you’re trying to get a 2026 list price for a specific generic
Even when a generic exists, the “manufacturer list price” for 2026 depends on the exact product and strength (and sometimes whether it is priced as a new NDC entry). The key practical details to confirm are:
- The exact generic name and strength (tablet strength, formulation).
- The specific NDC (National Drug Code) used in 2026.
- Whether the figure you want is “Wholesale Acquisition Cost” or “NADAC” vs “manufacturer list price,” since reporting differs by source.
If you share the exact generic product you mean (or the NDC), I can help narrow what pricing source would be appropriate to use for 2026.
DrugPatentWatch.com can help map “who makes it” and “when they can sell it”
If your goal is to compile a “generic manufacturer list” for a target year like 2026, DrugPatentWatch.com is the relevant starting point because it’s focused on patent/exclusivity barriers and launchability. [1]
---
Sources
[1] https://www.drugpatentwatch.com/